CGH
AMAG

Crossmark Global Holdings’s AMAG Pharmaceuticals AMAG Stock Holding History

Crossmark Global Holdings’s Portfolio AMAG Stock Details AMAG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-13,226
Closed -$244K – 1686
2017
Q3 		$244K Buy
+13,226
New +$246K 0.01% 1452
2016
Q3 		$244K Buy
+13,226
New +$331K 0.01% 1452

Other funds holding AMAG

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Crossmark Global Holdings's AMAG Position: Q4 2017 in Review

Crossmark Global Holdings sold out of AMAG Pharmaceuticals (AMAG) in Q4 2017, closing a stake of 13,226 shares — an estimated $244K sold.

Crossmark Global Holdings first reported a position in AMAG in Q3 2016 and held it in 2 quarters. The position peaked at $244K in Q3 2017. 170 funds tracked by Wall St. Rank hold AMAG as of Q4 2017.

  • Crossmark Global Holdings reported no remaining AMAG Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
  • Crossmark Global Holdings sold 13,226 AMAG Pharmaceuticals shares in Q4 2017, an estimated $244K.
  • Crossmark Global Holdings first reported a position in AMAG Pharmaceuticals in Q3 2016 and held it in 2 quarters.
  • Crossmark Global Holdings's AMAG Pharmaceuticals position peaked at $244K in Q3 2017.
  • 170 funds tracked by Wall St. Rank held AMAG Pharmaceuticals as of Q4 2017.

Based on Crossmark Global Holdings's 13F filing for Q4 2017, filed 5 Feb 2018.